NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NuVasive Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
NuVasive, Inc. (NUVA) has been struggling lately, but the selling pressure may be coming to an end soon.
Integra LifeSciences' Organic Growth Strong on New Products
by Zacks Equity Research
Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.
Medtronic Names Next CEO as Omar Ishrak to Step Down in 2020
by Zacks Equity Research
This is indeed a top story as during Omar's tenure, annual revenues of Medtronic (MDT) skyrocket to double-digit growth among a slew of enormous feats that he attains.
Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System
by Zacks Equity Research
With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.
Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe
by Zacks Equity Research
With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.
Quest Diagnostics' New Acquisitions and Pacts Aid Growth
by Zacks Equity Research
Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.
Why Is NuVasive (NUVA) Down 4.2% Since Last Earnings Report?
by Zacks Equity Research
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medtronic (MDT) Benefits from Strength Across Business Groups
by Zacks Equity Research
Within RTG, Medronic's (MDT) neurosurgery arm is gaining on strong uptake of Mazor X Stealth navigated robotic system.
Boston Scientific Closes BTG Buyout, PI Arm to Get a Boost
by Zacks Equity Research
In its effort to accommodate the acquisition of BTG, Boston Scientific (BSX) is offloading its certain non-prior businesses.
NUVA vs. LZAGY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. LZAGY: Which Stock Is the Better Value Option?
Here's Why You Should Invest in NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investor confidence is currently high on NuVasive's (NUVA) prospects.
Smith & Nephew (SNN) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Smith & Nephew (SNN) has been gaining from several positive developments of late.
National Vision's Store Launches on Track Despite Cost Woes
by Zacks Equity Research
National Vision (EYE) adopts a formula-based approach to open around 75 stores in 2019.
Abbott's Libre Adoption a Positive, Rhythm Management a Woe
by Zacks Equity Research
Abbott (ABT) is steadily riding high on a healthy growth track within its Diabetes Care business.
Zimmer Biomet Wins Nod for Spinal Teather to Treat Scoliosis
by Zacks Equity Research
Zimmer Biomet's (ZBH) AVBT solution, The Tether, uses a solid, flexible cord in place of traditional metal rods to pull on the outside of a scoliosis curve.
NuVasive's New TLIF Implant Broadens Spine Surgery Option
by Zacks Equity Research
NuVasive's (NUVA) Modulus TLIF-A is designed to work smoothly with the existing MAS TLIF and MAS Midline access systems.
Genomic Health Test to Guide Chemo Per New Breast Cancer Rule
by Zacks Equity Research
This is a major development in Genomic Health's (GHDX) endeavor to strengthen its breast cancer treatment portfolio.
Restoration Robotics (HAIR) Wins CE Mark for ARTAS iX System
by Zacks Equity Research
This regulatory approval is expected to strengthen Restoration Robotics' (HAIR) hair restoration business and expand its presence globally.
Edwards Lifesciences' (EW) SAPIEN 3 TAVR Receives FDA Nod
by Zacks Equity Research
Edwards Lifesciences (EW) plans a commercial introduction of SAPIEN 3 Ultra in Europe.
Here's Why You Should Hold Onto Omnicell (OMCL) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Omnicell's (OMCL) prospects.
QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results
by Zacks Equity Research
The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.
Baxter's PrisMax Adopted by Hamilton Health Care System
by Zacks Equity Research
Baxter's (BAX) PrisMax System first adopted by Hamilton Health, which in turn is expected to enhance patient care.
CVS Health Banks on Health Care Benefit Prospects Amid Woes
by Zacks Equity Research
CVS Health's (CVS) recently introduced Health Care Benefits segment following the Aetna acquisition is gaining a strong momentum.